Company Now Supplying More Than 40 Countries for Pandemic Vaccination Campaigns
FRANKLIN LAKES, N.J., June 8, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling 2 billion injection devices to support global COVID-19 vaccination efforts.
This new milestone reflects commitments to governments across the world, including the United States, Australia, Brazil, Canada, France, Germany, India, Philippines, Saudi Arabia, South Africa, Spain and the United Kingdom, among many others, as well as non-governmental organizations supporting vaccine deployment for developing countries. In total, BD is supporting pandemic orders for more than 40 countries, non-governmental organizations and other partners.
“Expanding vaccination efforts are bringing restored hope and a long-awaited return to normalcy in multiple countries around the world,” said Rick Byrd, president of Medication Delivery Solutions for BD. “We are committed to continuing to support government partners and non-governmental organizations in these efforts to ensure health care providers on the front lines of this crisis have these much-needed injection devices to protect their patients from COVID-19.”
BD has delivered more than 900 million injection devices around the world to date, with the remaining orders to be delivered between now and the end of 2022 to support vaccine administration. These devices are being shipped to governments or appointed distribution partners where they will then be distributed to health care facilities based on each country’s individual distribution and allocation strategy. BD continues to be in discussions with government agencies and non-governmental organizations on the need to plan ahead to ensure supply availability and place orders for delivery in late 2022 and into the future.
As part of its efforts, BD continues to closely plan supply capabilities to help ensure maximum volumes can be dedicated to COVID-19 efforts, while minimizing disruption for routine health care, annual flu vaccinations and childhood immunization programs.
BD has also announced multiple capital investments to expand capacity for vaccination injection devices for COVID-19 and future pandemics. These include:
- Partnering with the U.S. government on a $70 million capital project to further expand BD’s operations and manufacturing capacity in Nebraska. Once it is completed this summer, the federal government will have priority access to hundreds of millions of injection devices to support vaccination efforts for COVID-19 and future pandemics.
- Adding new manufacturing lines for injection devices in the company’s Fraga, Spain manufacturing facility. When these lines ramp up now through 2022 it will increase output of these devices by nearly 500 million per year to support COVID-19 and other efforts, mainly for markets in Europe, Middle East and Africa, as well as for non-governmental organizations.
- Investing $1.2 billion over four years to expand and upgrade BD’s manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems to allow for continued growth of new injectable drugs and vaccines. This will also provide surge capacity for increased pre-fillable syringe demand during times of pandemic response.
For this critical role and commitment to support vaccination efforts globally, BD was recently recognized at the 2021 World Vaccine Congress’ Vaccine Industry Excellence Awards as the “Best Production/Process Development.” The award recognized BD for its ability to extend its capacity to provide disposable syringes and pre-fillable syringes required for COVID-19 vaccinations, as well as its range of solutions covering the entire vaccine development.